Vodafone may apply for Unified Licence at appropriate time and obtain spectrum through market-related process for continuing the service in seven circles, the Telecom Dept has said
The Department of Telecom (DoT) has rejected Vodafone India's request to extend its licences in seven service areas that are expiring next year. In a note, the DoT said, "(Vodafone's) request for extension of licences in Kerala, Tamil Nadu, Haryana, Rajasthan, UP East, Maharashtra and Gujarat service areas expiring in December 2015 cannot be acceded".
Vodafone declined to comment.
In 2015-16, 29 licences are expiring, including seven held by Vodafone.
Vodafone applied to extend the licences under a provision allowing an extension of 10 years at the wish of the DoT. However, the official note said that circumstances have materially changed since the permits were granted in 1995 and the extension of licences is no longer conducive.
DoT cited a 2 February 2012, judgement of the Supreme Court, which cancelled 122 2G-licences that were allocated spectrum through an administrative process without being auctioned, provisions of the National Telecom Policy 2012, and the new licence regime among the reasons for rejecting Vodafone's request.
"Vodafone may apply for UL (Unified Licence) at appropriate time and obtain spectrum through market-related process for continuing the service in the service areas where the licences of Vodafone are going to expire in December 2015," the note said.
Meanwhile, the DoT has sought the recommendations of the Telecom Regulatory Authority of India for auctioning of spectrum in the 18 service areas where licences are expiring.
The 29 licence-holders in these areas together have about 198 megahertz of spectrum. Most of these licences have spectrum in the premium 900 MHz band for which telcos paid about two times more than the base price fixed by the government in the recent auction.
They hold about 172 MHz in 900 MHz, and 26 MHz in the 1800 MHz band.
In the February spectrum auction, bids of about Rs62,162 crore were received. In the total tally, bids worth Rs23,590 crore were received for 900 MHz spectrum in the Delhi, Mumbai and Kolkata service areas alone. The 1800 MHz band auction fetched bids worth Rs37,572.60 crore.
In addition to promoting the widespread use of opioids, the companies are alleged to have used their monetary might to influence at least 11 organizations in the promotion of opioid drug use for chronic pain
Weaving together a web of evil conspirators, including doctors and sham organizations, and secret alliances worthy of a John Grisham novel, California has brought a 100-page complaint against five pharmaceutical companies and their affiliates. The complaint alleges that they, together and independently, engaged in a “campaign of deception that: (1) misrepresented the efficacy of opioids, (2) trivialized or obscured their serious risks and adverse outcomes, and (3) overstated their superiority, compared with other treatments.”
The companies, according to the complaint, targeted the elderly and veterans, among others, and worked with front groups and doctors who helped disseminate misleading information about the safety and efficacy of the opioids.
There are five principle defendants in the case and some have been in trouble in the past:
1. Purdue Pharma L.P.: Purdue distributes OxyContin, which accounts for roughly 30% of the entire painkiller market and has annual sales of about $2.5 billion per year. Purdue settled criminal and civil charges against it for $635 million in 2007 for marketing misconduct and misbranding of OxyContin. Specifically, Purdue admitted in its plea that its promotion of OxyContin was misleading and inaccurate, misrepresented the risk of addiction, and was unsupported by science.
1. Cephalon, Inc.: Cephalon makes Actiq and Fentora, which are only approved by the FDA for the care of opioid-tolerant cancer patients. It pled guilty to a criminal violation of the Federal Food, Drug and Cosmetic Act and paid $425 million in 2008 for its misleading promotion of Actiq and two other drugs. Cephalon was found to have launched an illegal marketing campaign to sell Actiq to non-cancer patients suffering from chronic pain.
1. Janssen Pharmaceuticals, Inc.: Janssen sells Duragesic, Nucynta, Ultracet, and Ultram. Sales of Janssen opioids totaled $4.7 billion between 2009 and 2012.
1. Endo Health Solutions, Inc.: Endo makes Opana, Percocet, and Percodan. Sales of these opioids accounted for $403 million in revenues for Endo in 2012, and Opana yielded revenue of $1.16 billion between 2008 and 2012.
1. Actavis plc: It markets and sells Kadian and generic versions of Duragesic and Opana.
California charged that for the past two decades these companies have been engaged in a “common, sophisticated, and deeply deceptive marketing campaign” to convince health-care providers and the general public that compassionate treatment of chronic pain requires opioids. As a result of this alleged fallacy, the complaint said that:
The U.S. is now awash in opioids with 254 million prescriptions for opioids filled in the US in 2010 – enough to medicate every man and woman in America around the clock for a month.
The nation has an opioid-induced public-health epidemic with prescription opioid use contributing to almost 17,000 overdose deaths in 2010 – more than twice as many deaths as heroin and cocaine combined and surpassing motor vehicle accidents as a cause of death.
Sixty percent of opioid abusers report that their drugs originally came from prescriptions.
More than 12 million Americans age 12 and older used prescription painkillers without a prescription in 2013.
In order to mastermind this opioid epidemic, California asserts that the companies “supported, encouraged, and directed employees, front groups, and doctors they identified as ‘Key Opinion Leaders’ (‘KOL’) to publicize biased and misleading studies and promotional material and conduct thousands of medical education programs that were deceptive and lacked balance.”
The complaint singles out six physicians that it characterizes as paid puppets in the drug companies’ master plan to increase sales of opioids. Specifically, the state contends that these six doctors, among others:
have written, consulted on, edited, and lent their names to books and articles and given speeches and continuing medical education programs supportive of chronic opioid therapy. . . . Defendants cultivated and promoted only those KOLs who could be relied on to help broaden the opioid therapy market. Defendants selected and funded doctors whose public positions were unequivocal and supportive of using opioids to treat chronic pain.
The six principle physicians described in the complaint are:
1. Russell Portenoy: Dubbed the “King of Pain” by Time Magazine. Portenoy received “research support,” consulting fees and/or honoraria from the various companies and was a paid consultant to Cephalon and Purdue while he advocated that chronic opioid therapy was a safe and effective treatment for patients with intractable non-malignant pain.
2. Lynn Webster: Currently under investigation by the U.S. Drug Enforcement Administration as a result of more than 20 deaths of former patients from opioid overdoses, Webster has been an ardent supporter of chronic opioid therapy. He is senior editor of the Pain Medicine Journal, and past-president of the American Academy of Pain Medicine.
3. Scott Fishman: He served on the board of directors of the American Pain Foundations, which is described by California as a prominent front group for the companies’ deceptive marketing campaign.
4. J. David Haddox: A paid speaker and consultant for Purdue who promoted widespread opioid use for common non-cancer chronic pain. He subsequently became a Purdue employee and executive.
5. Perry Fine: Served on the board of directors of the American Pain Foundation with Fishman.
6. Kathleen Foley: Also served on the board of directors of the American Pain Foundation with Fishman and Fine.
The Front Groups
In addition to promoting the widespread use of opioids, the companies are alleged to have used their monetary might to influence at least eleven organizations in the promotion of opioid drug use for chronic pain. Said the complaint:
Taking a page from the tobacco industry’s play book, which had created and used front groups to proclaim tobacco was not harmful, Defendants harnessed and warped existing organizations to disseminate their deceptive messages with the expectation that these messages would circulate among and influence the conduct of prescribing physicians and other members of the medical community. These front organizations appeared to be legitimate scientific and patient advocacy organizations (and perhaps started out as such) and publicized seemingly scientific, balanced, and accurate information on opioid use. In fact, the information was false and misleading and paid for and encouraged by Defendants for the purpose of creating a vast market for the use of opioids for chronic pain.
The companies, the complaint said, influenced if not outright controlled the messages disseminated by the front groups, which received millions of dollars in grants and were aided by public relations firms hired by the companies to spread the misrepresentations central to their fraudulent promotion of opioids.
These “front groups” included:
1. American Pain Foundation: Described as the most prominent of the front groups, the APF is alleged to have issued education guides that promoted the benefits of opioids for chronic pain and trivialized their risks, particularly the risk of addiction. It launched a campaign to promote opioids for returning veterans. After receiving an inquiry from two U.S. senators, the APF closed its offices and dissolved the foundation before it was required to respond to the inquiry.
2. American Academy of Pain Medicine: The complaint alleges that with the assistance, prompting, involvement and funding of the companies, the AAPM issued treatment guidelines, and sponsored and hosted medical education programs critical to the companies’ deceptive marketing of chronic opioid therapy.
3. American Geriatric Society: According to the complaint, the AGS in 2009 revised its guidelines, which were thought to have been funded by Purdue and Janssen, for the Pharmacological Management of Persistent Pain in Older Persons. The revised guidelines included pro-opioid use for the elderly that is purportedly not supported by any reliable scientific evidence.
4. Pain Care Forum: This group was established and run by Purdue’s in-house lobbyist Burt Rosen and was substantially funded to promote the use of opioids for chronic non-cancer pain.
The complaint charges that the companies and the above cast of characters engaged in a multitude of deceptive marketing tactics knowing that their statements regarding the risks, benefits and superiority of opioids for chronic pain were untrue and unproven.
“Defendants had access to scientific studies, detailed prescription data, and reports of adverse events, including reports of addiction, hospitalization, and deaths – all of which made clear the significant adverse outcomes from opioids and that patients were suffering from addiction, overdoses, and death in alarming numbers.”
There can be no doubt that the allegations in this complaint tell a story of epic deception and corporate misconduct, which sets the stage for a mighty litigation battle. Just this week, Chicago filed a similar suit. For better or worse, however, odds are that in the years to come defendants will settle this case. TINA.org’s prediction is that at some point headlines will be written about a billion dollar plus settlement, and then these pharmaceutical companies will retreat quietly back to their offices ever ready to put profits above the health and well-being of their customers.
During January to March 2014, MMRDA paid Rs39.58 lakh to a private PR agency for its image building, reveals an RTI application
The Mumbai Metropolitan Region Development Authority (MMRDA) had paid Rs15.82 lakh per month to a public relations (PR) agency as part of its image building before the Lok Sabha election. This was revealed in a reply received by activist Anil Galgali under the Right to Information (RTI) Act.
In the reply, Dilip Kavatkar, joint project director of the Authority, said, "MMRDA appointed a PR Agency namely Ad Factors Pvt Ltd for a period of six months and paid them Rs39.58 lakh for a period from January 2014 to March 2014 and Rs7.86 lakh are in balance with MMRDA."
Maharashtra chief minister Prithivraj Chavan is the chairman of MMRDA. However, in his reply, Kavatkar claimed that there was no specific instruction from the chief minister on appointing the PR agency.
Between 2005 and 2011, MMRDA spent around Rs4 crore for its image building and appointed three PR agencies, Galgali said.
"MMRDA is a public authority and has its own PR department. Then why had it appointed a private agency and thereby wasting public funding? The PR agency was also provided an office in the MMRDA headquarters free of cost," Galgali alleged.
The RTI activist also filed a complaint with the chief minister, chief secretary and MMRDA commission requesting them not to use external and private PR agency.